IL103214A - Pharmaceutical preparations containing tachykinin antagonists for the treatment of nausea - Google Patents

Pharmaceutical preparations containing tachykinin antagonists for the treatment of nausea

Info

Publication number
IL103214A
IL103214A IL10321492A IL10321492A IL103214A IL 103214 A IL103214 A IL 103214A IL 10321492 A IL10321492 A IL 10321492A IL 10321492 A IL10321492 A IL 10321492A IL 103214 A IL103214 A IL 103214A
Authority
IL
Israel
Prior art keywords
emesis
formula
alkyl
treatment
use according
Prior art date
Application number
IL10321492A
Other languages
English (en)
Hebrew (he)
Other versions
IL103214A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL103214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919120172A external-priority patent/GB9120172D0/en
Priority claimed from GB929202839A external-priority patent/GB9202839D0/en
Priority claimed from GB929204151A external-priority patent/GB9204151D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL103214A0 publication Critical patent/IL103214A0/xx
Publication of IL103214A publication Critical patent/IL103214A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL10321492A 1991-09-20 1992-09-18 Pharmaceutical preparations containing tachykinin antagonists for the treatment of nausea IL103214A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919120172A GB9120172D0 (en) 1991-09-20 1991-09-20 Chemical compounds
GB929202839A GB9202839D0 (en) 1992-02-11 1992-02-11 Chemical compounds
GB929204151A GB9204151D0 (en) 1992-02-27 1992-02-27 Medicaments

Publications (2)

Publication Number Publication Date
IL103214A0 IL103214A0 (en) 1993-02-21
IL103214A true IL103214A (en) 1999-03-12

Family

ID=27265859

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10321492A IL103214A (en) 1991-09-20 1992-09-18 Pharmaceutical preparations containing tachykinin antagonists for the treatment of nausea

Country Status (14)

Country Link
US (7) US5360820A (de)
EP (4) EP0916346A3 (de)
JP (1) JP3020757B2 (de)
KR (1) KR100233323B1 (de)
AT (1) ATE195867T1 (de)
AU (1) AU657996B2 (de)
CA (1) CA2078578C (de)
DE (1) DE69231395T3 (de)
DK (1) DK0533280T4 (de)
ES (1) ES2149767T5 (de)
GR (1) GR3034682T3 (de)
IL (1) IL103214A (de)
PT (1) PT533280E (de)
TW (1) TW311139B (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807867A (en) * 1991-05-31 1998-09-15 Pfizer Inc. Quinuclidine derivatives
EP0916346A3 (de) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
AU676489B2 (en) * 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
EP0700384B1 (de) 1993-05-28 1997-07-16 Pfizer Inc. Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
FR2710842B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouvelle application thérapeutique de dérivés de perhydroisoindole.
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5491140A (en) * 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
MX9700271A (es) 1994-07-12 1997-05-31 Lilly Co Eli Antagonistas heterociclicos del receptor de taquinicina.
JPH10508837A (ja) * 1994-11-10 1998-09-02 ファイザー・インコーポレーテッド 眼の疾患を治療するためのｎｋ−１レセプターアンタゴニスト
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
RU2180852C2 (ru) * 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5565568A (en) * 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
AU5966096A (en) * 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
EP0912174B1 (de) * 1996-07-17 2004-04-28 MERCK & CO., INC. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5773458A (en) * 1996-10-30 1998-06-30 American Home Products Corporation 1-azabicycloheptane derivatives
EP0942728A1 (de) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Die verwendung von nk-1 rezeptor antagonisten für die behandlung von sexuellen fehlfunktionen
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
EP0942733B1 (de) * 1996-12-02 2005-04-27 MERCK SHARP & DOHME LTD. Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
CA2273806A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating substance use disorders
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
CA2273856A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US5846973A (en) * 1997-05-23 1998-12-08 Eli Lilly And Company Methods of treating pulmonary hypertension
WO1999007376A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
PL338456A1 (en) * 1997-08-06 2000-11-06 Lilly Co Eli 2-acylaminopropanoamines as antagonists of the tachykinin receptor
CA2298701A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
AU3993899A (en) * 1998-05-18 1999-12-06 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
WO2000032192A1 (fr) * 1998-11-27 2000-06-08 Takeda Chemical Industries, Ltd. Medicaments
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
BR0015320A (pt) 1999-11-03 2002-07-09 Albany Molecular Res Inc Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
EP1205855A3 (de) * 2000-11-10 2006-01-25 Masae Yanagi Verfahren, System und Vorrichtung zum Verwalten von Daten, Datenhandlungsgerät, Rechnerprogramm und Speichermedium
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
WO2003018586A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
EP1297826A1 (de) * 2001-09-27 2003-04-02 Menarini Ricerche S.p.A. Pharmazeutische Zusammensetzung zur nasalen Verabreichung enthaltend einen NK-2 Antagonisten
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
AU2003244455A1 (en) * 2002-02-08 2003-09-02 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
MXPA06009892A (es) * 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
JP5007226B2 (ja) 2004-07-15 2012-08-22 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリンならびにノルエピネフリン、ドーパミン、およびセロトニンの再取り込みを遮断するためのその利用方法
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
CA2615403C (en) 2005-07-15 2015-06-16 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2057151A4 (de) * 2006-08-28 2010-07-21 Hetero Drugs Ltd Verfahren zur reinigung von aprepitant
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (en) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AR066267A1 (es) * 2007-04-24 2009-08-05 Takeda Pharmaceutical Derivados de piperidina como antagonistas del receptor de taquiquinina
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
PH12012500713A1 (en) 2009-10-14 2012-11-26 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN108676800B (zh) 2010-08-17 2022-11-11 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
NO2729147T3 (de) 2011-07-04 2018-02-03
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2866797B1 (de) 2012-07-06 2020-04-29 Pharmathen S.A. Stabile injizierbare pharmazeutische zusammensetzung eines neurokinin-1-rezeptorantagonisten und verfahren zur herstellung davon
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
EP2925888B1 (de) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Zusammensetzungen und verfahren zur behandlung von krebs
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017021880A1 (en) 2015-08-03 2017-02-09 Leiutis Pharmaceuticals Pvt Ltd Liquid formulations of fosaprepitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3672964A4 (de) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Neuartige dreifachkombinationsformulierungen für antiemetische therapie
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4117673A1 (de) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Behandlung von stammzellenmangel

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US4175129A (en) * 1975-07-21 1979-11-20 Janssen Pharmaceutica N.V. Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives
US4160836A (en) * 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
GB2100259B (en) 1981-06-13 1984-10-31 Merrell Toraude & Co Treatment of migraine with tropyl benzoate derivatives
DE3445377A1 (de) 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
GB8401888D0 (en) 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
FR2610323B1 (fr) * 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
DE3711335A1 (de) 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
JPH01199575A (ja) 1988-02-04 1989-08-10 Rikagaku Kenkyusho 新規なサイクロマルトデキストリン・グルカノトランスフェラーゼ及びその製造法
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0363085A3 (de) * 1988-10-03 1991-03-27 Beecham Group Plc Chemische Verbindungen
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
EP0412798A3 (en) * 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
IE77033B1 (en) 1989-08-16 1997-11-19 Univ Tulane Substance P antagonists
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH0662607B2 (ja) 1989-11-28 1994-08-17 シンテックス（ユー・エス・エイ） インコーポレイテッド 新規三環式化合物
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5321032A (en) 1990-02-15 1994-06-14 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds and pharmaceutical compositions thereof
DE4007869A1 (de) 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
EP0550635B1 (de) * 1990-09-28 1995-04-19 Pfizer Inc. Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
US5242930A (en) * 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
CZ293954B6 (cs) 1991-03-26 2004-08-18 Pfizeráinc Postup přípravy substituovaných piperidinů
US5773450A (en) 1991-06-20 1998-06-30 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (de) 1991-06-21 1993-03-21 Pfizer
EP0593557B1 (de) 1991-07-05 1996-01-31 MERCK SHARP & DOHME LTD. Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
EP0916346A3 (de) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3503768B2 (ja) * 1995-01-06 2004-03-08 関西電力株式会社 溝掘削機の制御装置
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.

Also Published As

Publication number Publication date
IL103214A0 (en) 1993-02-21
EP0916346A2 (de) 1999-05-19
DE69231395T2 (de) 2001-02-01
US20020052351A1 (en) 2002-05-02
US7342028B2 (en) 2008-03-11
US5798363A (en) 1998-08-25
DK0533280T3 (da) 2001-01-02
EP0533280B1 (de) 2000-08-30
DE69231395D1 (de) 2000-10-05
EP0533280A1 (de) 1993-03-24
KR930017563A (ko) 1993-09-20
CA2078578A1 (en) 1993-03-21
US5538982A (en) 1996-07-23
DK0533280T4 (da) 2005-02-28
EP0533280B2 (de) 2004-12-01
DE69231395T3 (de) 2005-07-21
EP0919245A3 (de) 2000-11-15
US6326383B1 (en) 2001-12-04
CA2078578C (en) 2002-02-05
EP0916346A3 (de) 2000-12-06
ES2149767T5 (es) 2005-06-16
AU657996B2 (en) 1995-03-30
JP3020757B2 (ja) 2000-03-15
KR100233323B1 (ko) 1999-12-01
ES2149767T3 (es) 2000-11-16
US7214692B2 (en) 2007-05-08
AU2458392A (en) 1993-03-25
TW311139B (de) 1997-07-21
JPH06107563A (ja) 1994-04-19
US5360820A (en) 1994-11-01
PT533280E (pt) 2001-01-31
ATE195867T1 (de) 2000-09-15
US20050085414A1 (en) 2005-04-21
EP1082959A1 (de) 2001-03-14
EP0919245A2 (de) 1999-06-02
US6191139B1 (en) 2001-02-20
GR3034682T3 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
EP0533280B1 (de) Neue medizinische Indikation für Tachykinin-Antagonisten
JP5852611B2 (ja) （２ｓ，３ｒ）−ｎ−（２−（（３−ピリジニル）メチル）−１−アザビシクロ［２．２．２］オクタ−３−イル）ベンゾフラン−２−カルボキサミド、その新規塩形態およびその使用方法
JP2895630B2 (ja) ジアザビシクロニューロキニンアンタゴニスト
JP4295985B2 (ja) 新規なキヌクリジン誘導体およびそれを含む医薬組成物
US6812236B2 (en) Compounds useful in therapy
TR201807602T4 (tr) İmidazopiridin bileşikleri ve bunların kullanımları.
JP2965357B2 (ja) 三環式誘導体および薬剤におけるそれらの使用
JPH06500124A (ja) セロトニン作動性５―ｈｔ３拮抗薬として新規イミダゾピリジン
JPH05320162A (ja) ペプチド性キヌクリジン
JP2005524637A (ja) ピペリジン誘導体
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
WO2011075537A1 (en) Compounds for the treatment of neurologic disorders
JPH037229A (ja) 脳神経機能改善剤
TWI293299B (en) Novel quinuclidine derivatives and medicinal compositions containing the same
DE60119949T2 (de) 1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE ANWENDUNG IN DER BEHANDLUNG VON SCHMERZEN
JPH05310735A (ja) 置換３−アミノキヌクリジンｐ物質拮抗剤
JPH11349481A (ja) シグマ受容体結合剤
MXPA98010024A (en) Treatment of the prur

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired